Fujifilm to invest $1.2 billion in North Carolina plant in biopharma expansion

By Thomson Reuters Apr 11, 2024 | 12:55 PM

TOKYO (Reuters) -Japan’s Fujifilm will invest $1.2 billion to expand its North Carolina plant as part of its plans to expand biopharmaceutical contract manufacturing businesses in the United States and Europe, the company said on Thursday.

The investment will generate an additional 680 jobs at the unit Fujifilm Diosynth Biotechnologies’ facility in Holly Springs, North Carolina by 2031, the company said in a statement.

The Nikkei business daily reported on Friday that Fujifilm was planning a total $4.5 billion investment by 2028 in its global biopharmaceutical manufacturing sites, including in Japan and Europe.

Fujifilm is mulling over the expansion to quintuple its cell culture production capacity to about 750,000 litres and better compete against rivals including Switzerland’s Lonza, China’s Wuxi Biologics and South Korea’s Samsung Biologics, Nikkei said.

(Reporting by Kantaro Komiya; Editing by Chris Reese and Chizu Nomiyama)